Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2015 1
2016 1
2017 1
2018 3
2019 3
2020 4
2021 1
2022 4
2023 11
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial.
Ji L, Gao L, Jiang H, Yang J, Yu L, Wen J, Cai C, Deng H, Feng L, Song B, Ma Q, Qian L. Ji L, et al. Among authors: gao l. EClinicalMedicine. 2022 Oct 7;54:101691. doi: 10.1016/j.eclinm.2022.101691. eCollection 2022 Dec. EClinicalMedicine. 2022. PMID: 36247927 Free PMC article.
Chinese clinical guidelines for continuous glucose monitoring (2018 edition).
Bao Y, Chen L, Chen L, Dou J, Gao Z, Gao L, Guo L, Guo X, Ji L, Ji Q, Jia W, Kuang H, Li Q, Li Q, Li X, Li Y, Li L, Liu J, Ma J, Ran X, Shi L, Song G, Wang Y, Weng J, Xiao X, Xie Y, Xi G, Yang L, Zhao Z, Zhou J, Zhou Z, Zhu D, Zou D; Chinese Diabetes Society. Bao Y, et al. Among authors: gao l. Diabetes Metab Res Rev. 2019 Sep;35(6):e3152. doi: 10.1002/dmrr.3152. Epub 2019 Apr 25. Diabetes Metab Res Rev. 2019. PMID: 30884108 Review.
The effects of daily dose and treatment duration of metformin on the prevalence of vitamin B12 deficiency and peripheral neuropathy in Chinese patients with type 2 diabetes mellitus: A multicenter cross-sectional study.
Gao L, Ran X, Liu X, Shen X, Chen S, Liu F, Zhao D, Bi Y, Su Q, Lu Y, Lei M, Wang Y, Ji L. Gao L, et al. J Diabetes. 2023 Sep;15(9):765-776. doi: 10.1111/1753-0407.13428. Epub 2023 Jun 13. J Diabetes. 2023. PMID: 37310028 Free PMC article.
Personalized glucose-lowering effect of chiglitazar in type 2 diabetes.
Huang Q, Zou X, Chen Y, Gao L, Cai X, Zhou L, Gao F, Zhou J, Jia W, Ji L. Huang Q, et al. Among authors: gao l. iScience. 2023 Oct 12;26(11):108195. doi: 10.1016/j.isci.2023.108195. eCollection 2023 Nov 17. iScience. 2023. PMID: 37942014 Free PMC article.
Efficacy and safety of janagliflozin as add-on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin alone: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial.
Gao L, Cheng Z, Su B, Su X, Song W, Guo Y, Liao L, Chen X, Li J, Tan X, Xu F, Pang S, Wang K, Ye J, Wang Y, Chen L, Sun J, Ji L. Gao L, et al. Diabetes Obes Metab. 2023 Mar;25(3):785-795. doi: 10.1111/dom.14926. Epub 2022 Dec 12. Diabetes Obes Metab. 2023. PMID: 36433709 Clinical Trial.
A randomized, double-blind, placebo controlled, phase 3 trial to evaluate the efficacy and safety of cetagliptin added to ongoing metformin therapy in patients with uncontrolled type 2 diabetes with metformin monotherapy.
Ji L, Lu J, Gao L, Yan X, Li J, Cheng Z, Zhang L, Tian J, Li P, Bai J, Xie D, Zhao J, Ding J, Yu Q, Wang T. Ji L, et al. Among authors: gao l. Diabetes Obes Metab. 2023 Dec;25(12):3788-3797. doi: 10.1111/dom.15274. Epub 2023 Sep 19. Diabetes Obes Metab. 2023. PMID: 37724698 Clinical Trial.
25 results